p-Tau 181 / 217 (Plasma)
Phosphorylated tau (p-Tau 181 and 217) is a blood biomarker highly specific to Alzheimer's disease pathology, reflecting the tau protein changes that accompany the disease. A longevity practice tracks these emerging markers because they correlate closely with amyloid burden and can flag risk early.
What It Measures
The concentration of tau protein phosphorylated at threonine-217 (and 181) in plasma. These phospho-epitopes rise specifically with Alzheimer's disease (AD) neuropathology — abnormal amyloid-beta processing and tau tangle formation — and p-tau217 in particular tracks closely with amyloid-PET and cerebrospinal-fluid status, making it the most discriminative blood-based marker of AD pathology currently available.
Optimal vs. Lab Range
Target range for optimal health and longevity based on research.
Population-based reference range from standard labs.
Why It Matters
Phosphorylated tau — especially p-tau217 — has rapidly become the most clinically useful blood marker of Alzheimer's disease pathology. In head-to-head studies, plasma p-tau217 assays distinguish AD from other neurodegenerative conditions with an area under the curve around 0.95, approaching the performance of cerebrospinal fluid and amyloid-PET. In May 2025 the U.S. FDA cleared the first blood test to aid AD diagnosis — the Lumipulse G pTau217/beta-amyloid 1-42 plasma ratio — for symptomatic adults aged 55 and older, marking a shift toward accessible, blood-based detection. For a preventive, longevity-oriented practice, p-tau217 offers an early, minimally invasive signal of AD-type pathology, potentially years before clinical dementia, supporting earlier risk discussion and modifiable risk-factor management. It is an aid to assessment, not a stand-alone diagnosis, and results are interpreted by a physician in clinical context.
When Low
Below the assay's cutpoint: low probability of Alzheimer's-type amyloid/tau pathology at the time of testing. Continue risk-factor optimization and periodic reassessment as appropriate.
When Optimal
Values below the validated cutpoint indicate a low likelihood of AD pathology. Because thresholds are assay-specific, interpret against the reporting laboratory's reference and the overall clinical picture.
When High
Above the cutpoint: higher likelihood of Alzheimer's-type pathology. This warrants clinical correlation and, where appropriate, neurology referral and confirmatory testing (CSF or amyloid-PET). A single elevated result is an aid to diagnosis, not a diagnosis.
How to Optimize
p-tau reflects underlying disease biology rather than a lever to be "pushed," but the shared modifiable drivers of cognitive aging are worth optimizing: a Mediterranean/MIND dietary pattern, at least 150 minutes per week of aerobic activity plus resistance training, high-quality sleep (treating sleep apnea where present), tight control of blood pressure, glucose and ApoB, hearing correction, smoking cessation, and sustained cognitive and social engagement. Where p-tau and companion markers indicate likely AD pathology, disease-specific therapies (including anti-amyloid treatment) are considered under neurology guidance. This content is educational and not a substitute for medical advice.
Key Interventions & Linked Compounds
Strong (9/10)Key Interventions
Linked Compounds & Supplements
Curated from clinical literature. Individual results vary; consult a qualified clinician before changing a protocol.
Ordering Notes
Specimen
Plasma immunoassay (e.g., Lumipulse pTau217/Abeta42 ratio)
Patient prep
No fasting required. Maintain usual diet and medications unless advised.
Recommended cadence
As clinically indicated (e.g., cognitive concern or elevated risk); repeat per physician guidance
Reporting unit
pg/mL
Pre-analytic notes
Standardize draw time of day, hydration, and recent exercise. Note any acute illness, supplements, or hormonal therapies on the requisition.
Available panels
Recommended Follow-Up Actions
- 1
Confirm the result is reliable
Repeat abnormal values before acting — preferably from the same lab, same time of day, and under consistent prep. Rule out acute illness, recent intense exercise, or medication effects that can shift p-Tau 181 / 217 (Plasma).
- 2
Compare against optimal, not just lab range
Use the optimal window above as the target. Lab "normal" is built from the general population and often misses early dysfunction.
- 3
Pair with related markers
Order a complementary panel covering metabolic, inflammatory, and hormonal context to interpret this marker properly.
- 4
Discuss interventions with a clinician
Use the interpretation guidance above to frame the conversation. Bring trends, not just one datapoint, to your visit.
- 5
Re-test on a defined cadence
If a change is implemented, re-measure in 8–12 weeks for fast-moving markers, or 3–6 months for slower ones, to confirm response before escalating.
Testing Information
Recommended Frequency
As clinically indicated (e.g., cognitive concern or elevated risk); repeat per physician guidance
Fasting Requirement
No fasting required
Available Test Types
Quick Actions
Sample member
Longevity Operator
One number for your longevity journey.
FICO for credit. PHS for longevity. Eight biological domains collapsed into one provable score — intuitive at a glance, rigorous underneath.
- Metabolic
- Hormonal
- Cardiovascular
- Brain / Cognitive
- Sleep
- Musculoskeletal
- Gut
- Immunity / Inflammation
